Citations

Clear

9383 citation(s) found for "Thomas, PS".

The International Classification of Vestibular Disorders: Achievements, challenges, and future directions
Kaski, Diego , Tarnutzer, Alexander A. , Carey, John P. , Cha, Yoon‐Hee , Eggers, Scott D.Z. , Furman, Joseph M. , Kim, Hyun Ah , Lempert, Thomas , López‐Escámez, José A. , Magnusson, Måns , Newman‐Toker, David E. , Seemungal, Barry M. , Berg, Raymond van de , Brevern, Michael von , Bisdorff, Alexandre , Cha, Y H , Eggers, Scott Dz, Lempert, Thomas , López-Escámez, Jose A , Magnusson, Mans , Newman-Toker, David E , Seemungal, Barry M , Staab, Jeffrey P , Agrawal, Yuri , Kim, Ji‐Soo , Staab, Jeffrey P. , Strupp, Michael Leo , Ward, Bryan Kevin

Mayo Clinic

Journal of Vestibular Research | May 17, 2025 | Volume: 35 | Issue: 3 | Pages: 105-112

10.1177/09574271251313803 | PMID 39973600 Get It

In 2007, the Bárány Society embarked on a project to establish definitions of vestibular syndromes and disorders based on best available evidence, referred to as the International Classification of Vestibular Disorders (ICVD). Since then, numerous publications providing consensus-driven diagnostic criteria for vestibular symptoms, syndromes, and disorders have been published. Here, we reflect on the rationale for developing the ICVD as well as its subsequent achievements, challenges, and outlook. In this summary of the work of the ICVD to date, the authors will focus on practical aspects to help improve the utility and applicability of these diagnostic criteria moving forward.
Fetal Fraction Methodologies and Their Clinical Use: Results of a College of American Pathologists Exercise
Richards, C. Sue , Wyatt, Philip, Rowsey, Ross, Cacheris, Phillip Michael , Lepage, Nathalie , Natowicz, Marvin R. , Long, Thomas , Moyer, Ann M. , Richards, C. Sue , Rowsey, Ross A

Mayo Clinic

The Journal of Applied Laboratory Medicine | May 16, 2025 | Volume: 10 | Issue: 4 | Pages: 852-862

10.1093/jalm/jfaf062 | PMID 40376925 Get It

Abstract Background Noninvasive prenatal screening for common autosomal trisomies, sex chromosome aneuploidies and microdeletions vary by methodology and laboratory practice. The fetal portion of all cell-free DNA in the maternal circulation defines the fetal fraction (FF). The minimum specimen FF levels for reporting results vary between laboratories as well as the screening target (e.g., common trisomies vs select microdeletions). This variability can lead to confusion for both healthcare providers and patients. Methods Participants in the College of American Pathologists Non-Invasive Prenatal Testing 2021-B Exercise provided FF estimates for 3 manufactured samples. Responses to supplemental questions were also collected and analyzed. Results Overall, 72 of 77 participants responded. FF was measured by 66 participants using sequence counts (40), single nucleotide polymorphisms (15), fragment length (24), and Y chromosome sequences (24). Nearly half (48%) used multiple methods. For common trisomies, minimum FFs were none or <1% (n = 7), 1.0% to 3.9% (n = 35), 4.0% to 6.9% (n = 23), and ≥7.0% (n = 1); 4 participants did not measure FF. Challenge-specific FFs were variable with CVs of 13%, 15%, and 36%; the latter rate appears due to that sample’s fetal karyotype of 47,XYY. Comparing adjusted FF results for the 3 samples shows that 85% of participant results were within 20% of the consensus. Conclusions Using multiple methods to estimate FF was common, and cutoff levels for sample suitability varied widely. Within-laboratory FFs were less variable than between laboratories. Current FF estimates from clinical laboratories are not standardized and should be considered laboratory-specific.
Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine Carcinoma
Chiang, Anne C. , Nassar, Amin H. , Kim, Chul , Farhat, Elias Bou , Matteson, Kelsey, Lau, Shun‐Fat , Gallegos, Jesús Antonio Ocejo , Ardeshir‐Larijani, Fatemeh , Leal, Ticiana, Alam, Sumaye, Gray, Jhanelle E. , Hicks, J. Kevin , Kaldas, David , Baena, Javier, Berjaga, María Zurera, Grohé, Christian , Leuders, Heike, Mingo, Emanuele Claudio , Pancirer, Danny, Cheung, Justin M., Lin, Jessica, Watson, Alexander, Camidge, D. Ross , Parikh, Kaushal , Aggarwal, Vanya , Ahmed, Murtaza, Zhang, Jun , Nagasaka, Misako , Awosika, Nichola, Alhamad, Khaled, Zaman, Unaiza, Gupta, Divya , Lau, Chelsea, Khan, Hina, Liauw, Justin , Brown, Tyiesha , Mosteiro, Miguel , Lopes, Gilberto , Patrick, C. , Young, Lauren K. , Aljumaily, Raid, Mirza, Haris , TAKEBE, Y., Baena, Javier , Nassar, Amin H. , Ocejo Gallegos, Jesus Antonio , Bou Farhat, Elias , Espinar, Javier Baena , Adeyelu, Tolulope Tosin , Abushukair, Hassan , Rakaee, Mehrdad , Takabe, Yamato J. , Ramalingam, Suresh S. , Alam, Sumaiya, Nana, Frank Aboubakar , Citarella, Fabrizio , Cortellini, Alessio , Das, Millie , Ellis-Caleo, Timothy John , Linehan, William Marston , Sridhar, Arthi , Crowley, Fionnuala , Marron, Thomas , Sankar, K. Nathan , Kawtharany, Hassan , Owen, Dwight H , Li, Mingjia , Pinato, David J. , Puri, Sonam , Velázquez, Ana I. , Moliner, Laura , Rocha, Pedro , Evans, Mark G. , Vanderwalde, Ari M. , Elliott, Andrew , Nieva, Jorgé , Patrick, C. , Borghaei, Hossein , Lee, Matthew , Kwiatkowski, David J. , Herbst, Roy S. , Flavell, Richard A. , Naqash, Abdul Rafeh

Mayo Clinic

No container title available | May 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6639680/v1 Get It

Abstract Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung tumor marked by significant molecular heterogeneity. In a study of 590 patients across two independent cohorts, we observed comparable overall survival across treatment regimens (chemotherapy, chemoimmunotherapy, immunotherapy) without unexpected adverse events. Genomic analysis identified distinct NSCLC-like (KEAP1, KRAS, STK11 mutations) and SCLC-like (RB1, TP53 mutations) LCNEC subtypes, with 80% aligning with SCLC transcriptional profiles. Serial sampling revealed stable mutational but shifting transcriptomic landscapes over time. NSCLC-like LCNECs showed elevated FGL-1 (a LAG-3 ligand) and SPINK1 expression, while SCLC-like subtypes expressed higher levels of DLL3. Immunofluorescence confirmed FGL-1 in NSCLC-like LCNECs, and H&E slide analyses indicated fewer tumor-infiltrating lymphocytes in LCNECs versus other lung cancers. These findings highlight LCNEC’s distinct immunogenomic profile, supporting future investigations into LAG-3, SPINK1, and DLL3-targeted therapies.
Expert Strategies: Skull Base Reconstruction—Global Perspectives, Insights, and Algorithms through a Mixed Methods Approach
Talati, Vidit , Patel, Jagatkumar A. , Nguyen, Theodore V. , Pang, Jonathan C. , Liu, Lauren , Craig, John R. , Papagiannopoulos, Peter , Phillips, Katie M. , Tajudeen, Bobby A. , Adappa, Nithin D. , Sedaghat, Ahmad R. , Anand, Vijay K. , Batra, Pete S., Bergsneider, Marvin, Casiano, Roy R. , Cavallo, Luigi Maria , Cohen, Marc A. , Eloy, Jean Anderson , Evans, James J., Fernandez‐Miranda, Juan C. , Ferrari, Marco , Froelich, Sébastien , Gardner, Paul A. , Gray, Stacey T. , Hanna, Ehab Y., Harvey, Richard J. , Hong, Sang Duk , Hwang, Peter H. , Kong, Doo‐Sik , Lan, Ming‐Ying , Lee, John Y. K. , Levine, Corinna G. , Meço, Cem , Nicolai, Piero, Nyquist, Gurston , Omura, Kazuhiro , Patel, Zara M. , Celda, María Peris, Prevedello, Danny M., Rabinowitz, Mindy, Raza, Shaan M., Sargi, Zoukaa , Schlosser, Rodney J. , Schwartz, Theodore H. , Sindwani, Raj , Stamm, Aldo Cassol , Thorp, Brian D. , Wang, Marilene B. , Wang, Wei‐Hsin , Witterick, Ian , Won, Tae‐Bin , Woodworth, Bradford A. , Wormald, Peter‐John, Zada, Gabriel , Su, Shirley Y. , Kuan, Edward C , Talati, Vidit , Nguyen, Theodore V , Pang, Jonathan C , Craig, John R , Sedaghat, Ahmad R , Wang, Eric W , Ferrari, Marco , Georgalas, Christos , Harvey, Richard J , Hwang, Peter H , Lan, Ming-Ying , Omura, Kazuhiro , Patel, Zara , Neto, Carlos Pinheiro, Schlosser, Rodney J , Snyderman, Carl H , Woodworth, Bradford A , Meço, Cem , Su, Shirley Y , Abiri, Arash , Goshtasbi, Khodayar , Adappa, Nithin D. , Bergsneider, Marvin , Bernal‐Sprekelsen, Manuel , Bleier, Benjamin S. , Cappabianca, Paolo , Carrau, Ricardo L. , Castelnuovo, Paolo , Dallan, Iacopo , El‐Sayed, Ivan H. , Hanna, Ehab Y., Kelly, Daniel F. , Liu, James K. , Locatelli, Davide , McKean, Erin L. , Nicolai, Piero , Passeri, Thibault , Pinheiro‐Neto, Carlos , Prevedello, Danny M., Recinos, Pablo F. , Rosen, Marc R , Turri‐Zanoni, Mario , Wormald, Peter‐John

Mayo Clinic

International Forum of Allergy & Rhinology | May 15, 2025 | Volume: 15 | Issue: 10 | Pages: 1032-1069

10.1002/alr.23596 | PMID 40371737 Get It

ABSTRACT Objective There is limited consensus on endoscopic skull base surgery (ESBS) reconstruction principles. This study aims to generate comprehensive themes regarding ESBS reconstruction by pooling the experiences of ESBS experts, with comparison to a literature review of current published evidence. Methods Structured qualitative interviews of ESBS experts regarding postoperative management and reconstruction of various defect locations were conducted. Results A total of 68 experts comprising 40 academic teams across 13 countries with an average of 18 years of ESBS experience were included. We propose 10 stepwise algorithms for common skull base reconstruction scenarios based on these expert interviews. When available, the nasoseptal flap is used for all high_flow cerebrospinal leak defects. Multilayered reconstruction is favored at all anatomical subsites with increasing number of layers for increasing defect size and complexity. Heterogeneity exists in terms of inlay technique and materials, free grafting versus various pedicled flap options for low‐flow defects or in the absence of a nasal septum, nasal packing, tissue sealant, lumbar drain use, and postoperative management. Commonalities and discrepancies between experts were summarized. Conclusion Skull base reconstruction and post‐ESBS management is highly complex with a wide variety of practice patterns and expert strategies. Further research of higher quality evidence is warranted to identify optimal management patterns, though the current work aims to inform surgeons on these controversial areas by drawing from numerous experiences.
Optimal Target of Activated Clotting Time During PCI and Outcomes: The OPTIMAL-ACT Trial
Gharacholou, S. Michael , Thomas, Colleen S. , Hodge, David O. , Sabbagh, Abdallah El , Lane, Gary E. , Pollak, Peter , Pillai, Dilip, Johns, Gretchen S., Donato, Leslie J. , Singh, Mandeep , El Sabbagh, Abdallah , Pollak, Peter M , Pillai, Dilip P, Johns, Gretchen, Donato, Leslie

Mayo Clinic

Circulation: Cardiovascular Interventions | May 15, 2025 | Volume: 18 | Issue: 8 | Pages: No page available

10.1161/circinterventions.125.015291 | PMID 40371483 Get It

Quantification of Initial Symptom Relief Following Ultrasound-Guided Radiofrequency Ablation of Benign Thyroid Nodules
Atwell, Thomas D. , Schmitz, John J. , Ryder, Mabel , Roll, Rebecca J, Castro, M. Regina , Kassmeyer, Blake A., Kurup, A. Nicholas , Ryder, Mabel , Stan, Marius N.

Mayo Clinic

Ultrasound Quarterly | May 15, 2025 | Volume: 41 | Issue: 2 | Pages: No page available

10.1097/ruq.0000000000000716 | PMID 40369808 Get It

Abstract The use of radiofrequency ablation (RFA) of benign, symptomatic thyroid nodules is growing in clinical practice. Objective outcomes of symptom relief are needed to support the use of this treatment. Thus, a previously established thyroid nodule symptom scoring system was prospectively administered to patients prior to RFA of symptomatic thyroid nodules and then at 1, 3, 6, and 12 months following ablation. A total of 38 patients of mean age 57 years were treated with RFA between August 2022 and January 2024 and completed at least 1 follow-up survey. Five of these patients underwent simultaneous ablation of 2 thyroid nodules; the remainder had a single nodule treated. Mean modified symptom score prior to RFA was 3.5 (SD 1.6) with higher scores correlating with increasing baseline nodule volume (R = 0.46, P = 0.0038). Patient symptom scores decreased at the first 1-month survey (mean 1.2; SD 1.3) and 3-month survey (mean 0.9; SD 1.3) with durable response in those patients with more extended follow-up. In those patients with imaging follow-up, decreasing nodule size was shown to correlate with decreasing symptoms. The early results of this study show that RFA of benign, symptomatic thyroid nodules results in quantifiable symptom relief within 3 months of treatment. Such objective measures of symptom relief may be used to measure long-term durability of treatment.
The Feasibility of Investigating Acupuncture in Patients With COVID-19 Related Olfactory Dysfunction
Armstrong, Michael , O’Byrne, Thomas J., Calva, Jason J., Mallory, Molly J., Bublitz, Sara E. , Do, Alexander , O’Brien, Erin K. , Bauer, Brent A. , Stokken, Janalee K., Armstrong, Michael F , Mallory, Molly , Pinheiro Neto, Carlos D, Choby, Garret W, Bauer, Brent A , O'Brien, Erin K , Pinheiro‐Neto, Carlos , Choby, Garret

Mayo Clinic

Global Advances in Integrative Medicine and Health | May 14, 2025 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/27536130251343834 | PMID 40375879 Get It

Background Olfactory dysfunction (OD) is a common symptom in patients with coronavirus disease 2019 (COVID-19) with limited treatment options. Objective This pilot study aimed to investigate an acupuncture protocol in patients with COVID-19 related OD. Methods Thirty patients were randomized into 2 groups. The standard group was treated with budesonide nasal irrigation and olfactory training. The acupuncture group received ten sessions of acupuncture therapy in addition to the standard group treatment. Olfaction was assessed using the University of Pennsylvania Smell Identification Test, 10-point visual analog scale, and Sino-Nasal Outcome Test at baseline and after 3 months of treatment. Differences between study arms were compared using Fisher’s exact and Wilcoxon rank sum tests. Results Eighteen of the 30 (60%) enrolled patients completed the study, including 11 (73%) in the standard and 7 (47%) in the acupuncture group. Reasons for participant drop-out included cost of travel and time constraints. There were no acupuncture complications. Conclusions Acupuncture as an adjunct therapy for COVID-19 related OD is well tolerated. Subsequent studies with larger sample sizes are needed to assess the effect of acupuncture on OD.
Core GRADE 4: rating certainty of evidence—risk of bias, publication bias, and reasons for rating up certainty
Guyatt, Gordon , Eachempati, Prashanti, Hultcrantz, Monica , Chu, Derek K. , Flórez, Iván D. , Agoritsas, Thomas , Yao, Liang , Vandvik, Per Olav , Brignardello‐Petersen, Romina , Guyatt, Gordon , Chu, Derek K , Wang, Ying , Eachempati, Prashanti , Iorio, Alfonso , Murad, M. Hassan , Hemkens, Lars G. , Montori, Víctor M.

Mayo Clinic

BMJ | May 13, 2025 | Volume: 389 | Issue: No issue available | Pages: e083864

10.1136/bmj-2024-083864 | PMID 40360206 Get It

Deep Learning-Derived Cardiac Chamber Volumes and Mass From PET/CT Attenuation Scans: Associations With Myocardial Flow Reserve and Heart Failure
Hijazi, Waseem , Shanbhag, Aakash , Miller, Robert J.H. , Kavanagh, Paul , Killekar, Aditya , Lemley, Mark , Wopperer, Samuel, Knight, Stacey , Le, Viet T. , Mason, Steve, Rosamond, T. Thomas, Dey, Damini , Berman, Daniel S. , Carli, Marcelo F. Di , Acampa, Wanda , Dey, Damini , Berman, Daniel , Chareonthaitawee, Panithaya , Di Carli, Marcelo F , Slomka, Piotr J , Miller, Robert J H , Lemley, Mark , Shanbhag, Aakash , Knight, Stacey , Le, Viet T , Mason, Steve, Chareonthaitawee, Panithaya

Mayo Clinic

Circulation: Cardiovascular Imaging | May 13, 2025 | Volume: 18 | Issue: 7 | Pages: No page available

10.1161/circimaging.124.018188 | PMID 40357553 Get It

BACKGROUND: Computed tomography (CT) attenuation correction scans are an intrinsic part of positron emission tomography (PET) myocardial perfusion imaging using PET/CT, but anatomic information is rarely derived from these ultralow-dose CT scans. We aimed to assess the association between deep learning-derived cardiac chamber volumes (right atrial, right ventricular, left ventricular, and left atrial) and mass (left ventricular) from these scans with myocardial flow reserve and heart failure hospitalization. METHODS: We included 18 079 patients with cardiac PET/CT from 6 sites. A deep learning model estimated cardiac chamber volumes and left ventricular mass from CT attenuation correction imaging. Associations between deep learning-derived CT mass and volumes with heart failure hospitalization and reduced myocardial flow reserve were assessed in a multivariable analysis. RESULTS: During a median follow-up of 4.3 years, 1721 (9.5%) patients experienced heart failure hospitalization. Patients with 3 or 4 abnormal chamber volumes were 7× more likely to be hospitalized for heart failure compared with patients with normal volumes. In adjusted analyses, left atrial volume (hazard ratio [HR], 1.25 [95% CI, 1.19–1.30]), right atrial volume (HR, 1.29 [95% CI, 1.23–1.35]), right ventricular volume (HR, 1.25 [95% CI, 1.20–1.31]), left ventricular volume (HR, 1.27 [95% CI, 1.23–1.35]), and left ventricular mass (HR, 1.25 [95% CI, 1.18–1.32]) were independently associated with heart failure hospitalization. In multivariable analyses, left atrial volume (odds ratio, 1.14 [95% CI, 1.0–1.19]) and ventricular mass (odds ratio, 1.12 [95% CI, 1.6–1.17]) were independent predictors of reduced myocardial flow reserve. CONCLUSIONS: Deep learning–derived chamber volumes and left ventricular mass from CT attenuation correction were predictive of heart failure hospitalization and reduced myocardial flow reserve in patients undergoing cardiac PET perfusion imaging. This anatomic data can be routinely reported along with other PET/CT parameters to improve risk prediction.